Gales A, Sader H, Jones R N
University of Iowa College of Medicine, Iowa City, Iowa, USA.
Antimicrob Agents Chemother. 2001 May;45(5):1463-6. doi: 10.1128/AAC.45.5.1463-1466.2001.
The antimicrobial activity of BMS 284756, a novel des-F(6)-quinolone, was comparatively evaluated against 257 Streptococcus pneumoniae, 198 Haemophilus influenzae, and 88 Moraxella catarrhalis strains isolated in Latin America between July and September of 1999 as part of the SENTRY Antimicrobial Surveillance Program. Nearly 28.0% of S. pneumoniae strains were nonsusceptible to penicillin. The rank order of quinolone potency versus S. pneumoniae was BMS 284756 (MIC at which 90% of isolates were inhibited [MIC(90)], 0.12 microg/ml) > trovafloxacin (MIC(90), 0.25 microg/ml) > gatifloxacin (MIC(90), 0.5 microg/ml) > levofloxacin and ciprofloxacin (MIC(90), 1 to 2 microg/ml). All S. pneumoniae strains that were not susceptible to other quinolones were inhibited by BMS 284756 at < or = 2 microg/ml. The overall prevalence of beta-lactamase production was 15.2% in H. influenzae and 98.9% in M. catarrhalis. BMS 284756 showed excellent potency and spectrum against this group of pathogens, inhibiting all isolates at < or = 0.12 microg/ml. BMS 284756 exhibited activity similar to those displayed by the new fluoroquinolones, such as levofloxacin, trovafloxacin, or gatifloxacin, and could be a therapeutic option for empirical treatment of community-acquired respiratory tract infections.
作为哨兵抗菌监测项目的一部分，对1999年7月至9月间在拉丁美洲分离出的257株肺炎链球菌、198株流感嗜血杆菌和88株卡他莫拉菌，比较评估了新型去F(6)-喹诺酮BMS 284756的抗菌活性。近28.0%的肺炎链球菌菌株对青霉素不敏感。喹诺酮类药物对肺炎链球菌的效力排序为：BMS 284756（90%分离株被抑制时的最低抑菌浓度[MIC(90)]，0.12μg/ml）>曲伐沙星（MIC(90)，0.25μg/ml）>加替沙星（MIC(90)，0.5μg/ml）>左氧氟沙星和环丙沙星（MIC(90)，1至2μg/ml）。所有对其他喹诺酮类药物不敏感的肺炎链球菌菌株都能被浓度≤2μg/ml的BMS 284756抑制。流感嗜血杆菌中β-内酰胺酶产生的总体发生率为15.2%，卡他莫拉菌中为98.9%。BMS 284756对这组病原体显示出优异的效力和抗菌谱，能抑制所有浓度≤0.12μg/ml的分离株。BMS 284756表现出与新型氟喹诺酮类药物（如左氧氟沙星、曲伐沙星或加替沙星）相似的活性，可能是社区获得性呼吸道感染经验性治疗的一种选择。
